(NewsDirect)
Amplia Therapeutics Ltd (ASX:ATX) CEO Dr Chris Burns speaks withProactive following his move into the leadership role late last year.Amplia is an Australian pharmaceutical company advancing a pipeline ofFocal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK isan increasingly important target in cancer and Amplia has a particulardevelopment focus in fibrotic tumours such as pancreatic and ovariancancers.
ContactDetails
Proactive Investors
JonathanJackson
+61 413 713 744
jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.